Skip to main content
OpenTrials
Completed

NCT Number: NCT02055222

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta <=1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

About this study

Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • INCLUSION CRITERIA: For subjects with lung diseases:
  • Men and women age 40-80 years
  • Smokers with greater than or equal to 10 pack-year history of ever-smoking

Exclusion criteria

For subjects with lung diseases:

Subjects will be excluded from the study if they meet one or more of the following criteria:

  • Subjects who are under the age of 40 or over 80 years old
  • Women who are pregnant or lactating
  • Have known allergies to lidocaine or medications used for moderate sedation
  • Active coronary artery disease
  • Cerebral-vascular accident within the past 12 months
  • Active anticoagulation
  • Active infections
  • Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
  • Poorly controlled chronic diseases
  • Unable to provide consent
  • Impaired renal function (including dialysis)
  • Contraindications to MRI scan including:
  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing
  • pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

Inclusion criteria

For Non-Smoking Controls

  • Men and women age 40-80 years
  • No prior history of smoking (this is a non-smoking cohort)

Exclusion criteria

For Non-Smoking Controls

  • Subjects who are under the age of 40 or over 80 years old
  • Women who are pregnant or lactating
  • Have known allergies to lidocaine or medications used for moderate sedation
  • Active coronary artery disease
  • Cerebral-vascular accident within the past 12 months
  • Active anticoagulation
  • Active infections
  • Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
  • Poorly controlled chronic diseases
  • Unable to provide consent
  • Impaired renal function (including dialysis)
  • Contraindications to MRI scan including:
  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing
  • pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

Inclusion criteria

For Smoking Controls

  • Men and women age 40-80 years
  • Subjects who have a prior smoking history

Exclusion criteria

For Smoking Controls

  • Subjects who are under the age of 40 or over 80 years old
  • Women who are pregnant or lactating
  • Have known allergies to lidocaine or medications used for moderate sedation
  • Active coronary artery disease
  • Cerebral-vascular accident within the past 12 months
  • Active anticoagulation
  • Active infections
  • Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence).
  • Poorly controlled chronic diseases
  • Unable to provide consent
  • Impaired renal function (including dialysis)
  • Contraindications to MRI scan including:
  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing
  • pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder

Treatment and study plan

Primary outcomes

  1. Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD.

    Time frame: 3 years

    Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD

Sponsors and collaborators

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Nih

Registry information

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Feb 5, 2014
Registry last updated
Jun 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.